06:03 AM EDT, 10/07/2025 (MT Newswires) -- Dyne Therapeutics ( DYN ) said Monday additional one-year data from its ongoing phase 1/2 trial of zeleciment basivarsen, or z-basivarsen, in patients with myotonic dystrophy type 1 demonstrated "clinically meaningful improvements" in strength and function using the selected registrational dose.

New data include improvements in scores that measure upper limb function, strength in upper and lower extremities, as well as mobility and ability to do activities, according to Dyne Therapeutics ( DYN ).

The data from the 56 patients enrolled under the trial's selected registrational dose also demonstrated the product candidate's "favorable safety profile," the company added.